Exscientia Reaches Key Milestones in Two Programs Under Sanofi Collaboration
Exscientia has achieved significant progress in two discovery programs under its collaboration with Sanofi, earning $15 million in milestone payments. These programs have advanced to the core optimization phase, meeting the product profile requirements set by both companies. The two lead compounds show strong differentiation in early profiling, with the potential to become first-in-class therapies.
The partnership now includes three programs in early development, with several others at earlier stages. This progress underscores Exscientia’s ability to design highly differentiated molecules that address complex therapeutic challenges. David Hallett, PhD, Interim CEO and Chief Scientific Officer of Exscientia, expressed confidence in the collaboration’s potential to provide new treatment options for patients with unmet medical needs. He highlighted the company’s ongoing commitment to advancing these programs alongside Sanofi.
The $15 million payment is expected to be received in the fourth quarter of 2024, and will be recorded as revenue over the collaboration’s term. Additionally, Exscientia is eligible for more than $600 million in pre-commercial and commercial milestone payments if the programs achieve specific research, regulatory, and market objectives. The agreement also includes tiered royalties on future product sales, ranging from single to double-digit percentages.
Exscientia is a technology-driven company dedicated to revolutionizing drug discovery and development through the integration of artificial intelligence (AI) and automation. By combining precision design with experimental research, Exscientia aims to create more effective medicines faster. The company pioneered the use of AI in drug discovery, becoming the first to advance AI-designed small molecules into clinical trials. While its internal pipeline focuses on oncology, the company’s partnerships, including this collaboration with Sanofi, extend across various therapeutic areas.
Exscientia’s innovative approach seeks to change the economics of drug discovery, accelerating the process from scientific ideas to patient-ready medicines. By leveraging AI, automation, and engineering, the company is positioned to rapidly develop high-quality drug candidates that address significant medical challenges.
